Other News To Note
Celgene International Sàrl, of Boudry, Switzerland, submitted a marketing authorization application for the approval of Revlimid (lenalidomide) as a maintenance treatment for newly diagnosed multiple myeloma patients who have not progressed following initial treatment with melphalan, prednisone and Revlimid, or following autologous stem cell transplantation.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST